Cladribine tablets and multiple sclerosis: NICE technology appraisal

被引：0
|
作者：
Gaber, Tarek [1 ]
Shippen, Clare [2 ]
机构：
[1] Wrightington Wigan & Leigh NHS Fdn Trust, Neurol Rehabil, Wigan, England
[2] North West Deanery, Rehabil Med, Manchester, Lancs, England
来源：
PROGRESS IN NEUROLOGY AND PSYCHIATRY | 2018年 / 22卷 / 01期
关键词：
D O I：
10.1002/pnp.486
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Cladribine is the first disease modifying treatment (DMT) for relapsing remitting multiple sclerosis (RRMS) that progressed straight to a positive final recommendation in the NICE appraisal process. The final recommendations were published in December 2017.(1) An agreement between NHS England and Merck, the manufacturer of cladribine (Mavenclad), will allow MS patients who are suffering from highly active or rapidly evolving RRMS to access the drug. Here, the authors discuss the clinical and economic considerations for cladribine usage.
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [21] Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
    Gavin Giovannoni
    Joela Mathews
    Neurology and Therapy, 2022, 11 : 571 - 595
  • [22] Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis
    Cook, Stuart
    Leist, Thomas
    Comi, Giancarlo
    Montalban, Xavier
    Giovannoni, Gavin
    Nolting, Axel
    Hicking, Christine
    Galazka, Andrew
    Sylvester, Elke
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 29 : 157 - 167
  • [23] Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis
    Cook, Stuart
    Giovannoni, Gavin
    Leist, Thomas
    Syed, Sana
    Nolting, Axel
    Damian, Doris
    Schick, Regina
    NEUROLOGY, 2019, 92 (15)
  • [24] Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis
    Cook, S.
    Giovannoni, G.
    Leist, T.
    Syed, S.
    Nolting, A.
    Schick, R.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 465 - 466
  • [25] Long-term experience with cladribine tablets in multiple sclerosis patients
    Oreja-Guevara, Celia
    Gomez Estevez, Irene
    Garcia Vasco, Lorena
    Quezada Sanchez, Johnny
    Diaz, Judit
    Gil-Perotin, Sara Garcia
    Alba Suarez, Elda Maria
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 966 - 966
  • [26] Study of B cells in subjects with multiple sclerosis treated with cladribine tablets
    Pirronello, Marta
    Picozza, Mario
    Guerrera, Gisella
    Corbisiero, Silvia
    D'Orso, Silvia
    Lista, Beatrice
    Misiti, Andrea
    Ruggieri, Serena
    Quartuccio, Esmeralda
    Buscarinu, Maria Chiara
    De Masi, Francesca
    Tortorella, Carla
    Salvetti, Marco
    Gasperini, Claudio
    Borsellino, Giovanna
    Battistini, Luca
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 641 - 642
  • [27] Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis
    Cook, S.
    Giovannoni, G.
    Leist, T.
    King, J.
    Syed, S.
    Nolting, A.
    Schick, R.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 469 - 469
  • [28] Cladribine tablets in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRibine tablets Treating multiple sclerosis orallY) extension study
    Rieckmann, Peter
    Giovannoi, Gavin
    Cook, Stuart D.
    Greenberg, S.
    Chang, Peter
    Comi, Giancarlo
    Sorensen, Per Soelberg
    Vermersch, Patrick
    MULTIPLE SCLEROSIS, 2008, 14 : S161 - S162
  • [29] Real-World Outcomes With Cladribine Tablets in People With Relapsing Multiple Sclerosis
    Okuda, Darin
    Livingston, Terrie
    Moog, Tatum
    Smith, Alexander
    Lebson, Lori
    Piette, Elizabeth
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1100 - 1100
  • [30] Clinical development plan for cladribine tablets, an oral immunomodulator, for the treatment of multiple sclerosis
    Viglietta, V.
    Greenberg, S.
    Mikol, D.
    Weiner, J.
    Alteri, E.
    Chang, P.
    Krumwieh, D.
    Musch, B.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S126 - S126
12345